NUCB1 and neoplasm: In high risk/ERα+ subgroups, if the tumours were SHON-Nuc−, administration of tamoxifen had no impact on the survival [HR (95% CI) = 0.85 (0.63–1.16), p = 0.302] (Fig. 2f), whereas if the tumours were also SHON-Nuc+, tamoxifen treatment resulted in improved survival and a reduced risk of death from BC by 79% [HR (95% CI) = 0.21 (0.08–0.56), p = 0.002] (Fig. 2g).